Deutsche Bank AG started coverage on shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) in a report issued on Tuesday morning. The firm issued a hold rating and a $30.00 target price on the specialty pharmaceutical company’s stock.

A number of other research firms also recently issued reports on VRX. Morgan Stanley reiterated a positive rating on shares of Valeant Pharmaceuticals International in a research report on Friday, August 19th. RBC Capital Markets set a $36.00 target price on shares of Valeant Pharmaceuticals International and gave the company a hold rating in a research report on Friday, August 19th. Jefferies Group reiterated a buy rating and set a $40.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, August 10th. Scotiabank reiterated a sector perform rating and set a $32.00 target price (down previously from $35.00) on shares of Valeant Pharmaceuticals International in a research report on Tuesday, July 26th. Finally, Wells Fargo & Co. reiterated a sell rating and set a $19.50 target price (down previously from $27.50) on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 7th. Six research analysts have rated the stock with a sell rating, fifteen have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Hold and a consensus target price of $56.09.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) opened at 26.85 on Tuesday. Valeant Pharmaceuticals International has a 52 week low of $18.55 and a 52 week high of $214.72. The firm has a 50-day moving average of $27.95 and a 200-day moving average of $29.09. The firm’s market cap is $9.33 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.48 by $0.08. The firm earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The firm’s revenue for the quarter was down 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.14 EPS. On average, analysts expect that Valeant Pharmaceuticals International will post $6.53 EPS for the current year.

In related news, Director Argeris N. Karabelas purchased 4,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Thursday, August 11th. The stock was purchased at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the acquisition, the director now directly owns 20,726 shares of the company’s stock, valued at $510,895.90. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 16.37% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in VRX. Acrospire Investment Management LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter valued at approximately $108,000. Tower Research Capital LLC TRC increased its stake in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares during the last quarter. Cacti Asset Management LLC increased its stake in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 3,400 shares during the last quarter. AGF Investments Inc. increased its stake in Valeant Pharmaceuticals International by 121.9% in the second quarter. AGF Investments Inc. now owns 8,842 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 4,857 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. acquired a new stake in Valeant Pharmaceuticals International during the first quarter valued at approximately $200,000. Institutional investors own 64.77% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.